In this Q&A, Francisco Polidoro, Junior, PhD, discusses the basics of the drug review and approval process, current challenges, and areas for improvement
Expanded capabilities in company’s Immunogenicity and Immuno-oncology QSP Simulators broaden applicability for addressing safety and efficacy challenges